Eli Lilly And Co vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Eli Lilly And Co trades at $1,179.71 (market cap $1.02T), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: Eli Lilly And Co pays a 0.6% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| LLY | TSLY | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.24K | $48.25 |
52-Week Low | $625.65 | $25.07 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $25.07, down 2.57% today amid a bearish technical signal. The ETF generates high income through weekly distributions, with recent dividends ranging from $0.26 to $0.52 per share, but faces criticism for capping upside during Tesla rallies. Its strategy relies on synthetic Tesla exposure and covered call overlays, producing an annualized yield near 52.65%, though distributions are largely return of capital.
The outlook is cautious due to structural limitations that sacrifice capital appreciation for income, with risks including volatility from Tesla's performance and option strategy complexity. Investors prioritizing yield may find value, but those seeking growth could underperform Tesla's equity returns.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →